Markets
PJP

Why These Pharma ETFs Rallied on Thursday

A generic image of many stacks of coins
Credit: Shutterstock photo

Pharma ETFs have seen solid trading on Feb 28 as positive drug data and events in the cannabis industry were cheered by investors. Despite the ongoing controversy related to high drug prices, fundamentals appear to be strong for the space. The merger and acquisition backdrop has also been solid in the industry (read: Bristol-Myers to Acquire Celgene: Healthcare ETFs in Focus ).

Arcadia Eyes Cannabis Industry

Arcadia Biosciences Inc.RKDA - which normally develops food ingredients from wheat and soybeans - saw its shares jump 49% on Feb 28 after it announced plans to foray into the hot hemp or cannabis industry (read: Top ETF Stories of February ).

Congress-legalized hemp products , including most CBD, in December in the 2018 Farm Bill. This change has paved the way for the formation of Arcadia Specialty Genomics, which now seeks to tap the rising demand in the hot marijuana space.

Horizon Pharma's Positive Trial of Eye Disease Treatment

Horizon Pharma Public Limited CompanyHZNP saw around a 33% jump on Feb 28 as it announced positive results in a late-stage trial of a treatment for active thyroid eye disease, or TED, per the source . The trial successfully met the secondary endpoints and realized a consistent safety profile with the phase 2 study. The company is looking to submit a biologics license application to the FDA in mid-2019.

TG Therapeutics Comes Up With Positive Umbralisib Data

This Zacks Rank #1 (Strong Buy) biopharmaceutical company TGTX saw its shares jump 31% on Feb 28, thanks to positive results from a Phase 2b clinical trial, UNITY-NHL, evaluating umbralisib in patients with treatment-resistant non-Hodgkin lymphoma (NHL). Preliminary data will be presented at AACR on Apr 1 .

Decent Earnings Season

The space has been coming up with decent corporate results. Per the Earnings Trends issued on Feb 20, 2019, earnings growth in the fourth quarter is likely to be 10.2% on 7.9% higher revenues (read: A Look at Pharma ETFs Post Q4 Results ).

ETFs in Focus

Below we highlight a few top-ranked ETFs that added more than 1% on Feb 28 and have been trading around a one-month high.

First Trust Nasdaq Pharmaceuticals ETF FTXH - Up 2.1% on Feb 28

SPDR S&P Pharmaceuticals ETFXPH - Up 2.0% on Feb 28

iShares US Pharmaceuticals ETFIHE - Up 1.3% on Feb 28

Invesco Dynamic Pharmaceuticals ETFPJP - Up 1.2% on Feb 28

Want key ETF info delivered straight to your inbox?

Zacks' free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week. Get it free >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

SPDR S&P Pharmaceuticals ETF (XPH): ETF Research Reports

iShares U.S. Pharmaceuticals ETF (IHE): ETF Research Reports

Invesco Dynamic Pharmaceuticals ETF (PJP): ETF Research Reports

TG Therapeutics, Inc. (TGTX): Free Stock Analysis Report

Horizon Pharma Public Limited Company (HZNP): Free Stock Analysis Report

Arcadia Biosciences, Inc. (RKDA): Free Stock Analysis Report

First Trust NASDAQ Pharmaceuticals ETF (FTXH): ETF Research Reports

To read this article on Zacks.com click here.

Zacks Investment Research

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

PJP TGTX HZNP XPH IHE

Other Topics

ETFs

Latest Markets Videos

    Zacks

    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

    Learn More